Population pharmacokinetic model of canrenone after intravenous administration of potassium canrenoate to paediatric patients

Paul Collier, Jeffrey Millership, Prashant Kole, H. Halliday, James McElnay, Mike Shields, Maysa Suyagh, Ahmed Hawwa, Muriel Millar

Research output: Contribution to journalArticlepeer-review

2 Citations (Scopus)
224 Downloads (Pure)

Abstract

Objectives: To characterize the population pharmacokinetics of canrenone following administration of potassium canrenoate in paediatric patients. Patients and Methods: Data were collected prospectively from 23 paediatric patients (2 days to 10 years of age; median weight 4 kg, range 2.16-28.0 kg) who received intravenous potassium canrenoate (K-canrenoate) as part of their intensive care therapy for removal of retained fluids e.g. in pulmonary oedema due to chronic lung disease and for the management of congestive heart failure. Plasma samples were analysed by HPLC for determination of canrenone (the major metabolite and pharmacologically active moiety) and the data subjected to pharmacokinetic analysis using NONMEM. Results: A one-compartment model best described the data. The only significant covariate was weight (WT). The final population models for canrenone clearance (CL/F) and volume of distribution (V/F) were CL/F (L/hr) = 11.4 × (WT /70.0)(0.75) and V/F (L) = 374.2 × (WT/70) where WT is in kg. The values of CL/F and V/F in a 4 kg child would be 1.33 L/hr and 21.4 L, respectively, resulting in an elimination half-life of 11.2 hr. Conclusions: The range of estimated CL/F in the study population was 0.67-7.38 L/hr. The data suggest that adjustment of K-canrenoate dosage according to body weight is appropriate in paediatric patients
Original languageEnglish
Pages (from-to)864-872
Number of pages9
JournalBritish Journal of Clinical Pharmacology
Volume74
Issue number5
DOIs
Publication statusPublished - 01 Nov 2012

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology

Fingerprint

Dive into the research topics of 'Population pharmacokinetic model of canrenone after intravenous administration of potassium canrenoate to paediatric patients'. Together they form a unique fingerprint.

Cite this